SG11201408554QA - Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof - Google Patents
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereofInfo
- Publication number
- SG11201408554QA SG11201408554QA SG11201408554QA SG11201408554QA SG11201408554QA SG 11201408554Q A SG11201408554Q A SG 11201408554QA SG 11201408554Q A SG11201408554Q A SG 11201408554QA SG 11201408554Q A SG11201408554Q A SG 11201408554QA SG 11201408554Q A SG11201408554Q A SG 11201408554QA
- Authority
- SG
- Singapore
- Prior art keywords
- jagged
- antibodies
- methods
- cross
- activatable
- Prior art date
Links
- 102000049546 Jagged-2 Human genes 0.000 title 1
- 101710170213 Protein jagged-2 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663307P | 2012-06-22 | 2012-06-22 | |
US201361749212P | 2013-01-04 | 2013-01-04 | |
US201361749486P | 2013-01-07 | 2013-01-07 | |
US201361755810P | 2013-01-23 | 2013-01-23 | |
PCT/US2013/047109 WO2013192550A2 (en) | 2012-06-22 | 2013-06-21 | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408554QA true SG11201408554QA (en) | 2015-02-27 |
Family
ID=49769724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408554QA SG11201408554QA (en) | 2012-06-22 | 2013-06-21 | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
Country Status (18)
Country | Link |
---|---|
US (4) | US9127053B2 (es) |
EP (1) | EP2863948B1 (es) |
JP (1) | JP2015521625A (es) |
KR (1) | KR20150037857A (es) |
CN (1) | CN104661677A (es) |
AU (1) | AU2013278075B2 (es) |
BR (1) | BR112014031689A2 (es) |
CA (1) | CA2876904C (es) |
CO (1) | CO7151488A2 (es) |
HK (1) | HK1204576A1 (es) |
IL (1) | IL236348A0 (es) |
IN (1) | IN2014MN02635A (es) |
MX (1) | MX2014016038A (es) |
PE (1) | PE20150643A1 (es) |
PH (1) | PH12015500125A1 (es) |
RU (1) | RU2015101803A (es) |
SG (1) | SG11201408554QA (es) |
WO (1) | WO2013192550A2 (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014004074A (es) | 2011-10-05 | 2014-06-05 | Genentech Inc | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. |
GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
RU2018130986A (ru) | 2012-08-13 | 2018-10-09 | Дженентек, Инк. | Антитела к jagged и способы их применения |
RU2015132436A (ru) | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
US10350216B2 (en) * | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
GB201300706D0 (en) * | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
JP6527132B2 (ja) | 2013-03-15 | 2019-06-05 | ジェネンテック, インコーポレイテッド | 肝臓がんの診断及び治療のための組成物及び方法 |
US10633453B2 (en) | 2013-05-28 | 2020-04-28 | Kaohsiung Medical University | Antibody locker for the inactivation of protein drug |
RU2015156888A (ru) * | 2013-06-04 | 2017-07-14 | Сайтомкс Терапьютикс, Инк. | Композиции и методы конъюгирования активируемых антител |
ES2912932T3 (es) * | 2013-07-25 | 2022-05-30 | Cytomx Therapeutics Inc | Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y procedimientos de uso de los mismos |
RU2715232C2 (ru) | 2013-09-25 | 2020-02-26 | Сайтомкс Терапьютикс, Инк. | Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования |
EP4176896A1 (en) * | 2014-01-31 | 2023-05-10 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
WO2015123325A1 (en) * | 2014-02-12 | 2015-08-20 | Genentech, Inc. | Anti-jagged1 antibodies and methods of use |
AU2015254913B2 (en) | 2014-04-29 | 2018-05-17 | Novartis Ag | Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest |
KR20170029490A (ko) | 2014-07-11 | 2017-03-15 | 제넨테크, 인크. | 노치 경로 억제 |
JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス,インコーポレイティド | 抗-cd3抗体、活性化可能抗-cd3抗体、多重特異的抗-cd3抗体、多重特異的活性化可能抗-cd3抗体、及びそれらの使用方法 |
TWI759810B (zh) * | 2014-08-08 | 2022-04-01 | 美商Alx腫瘤技術股份有限公司 | 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途 |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
WO2016129656A1 (ja) * | 2015-02-12 | 2016-08-18 | 国立大学法人岩手大学 | 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤 |
MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
SI3292149T1 (sl) | 2015-05-04 | 2022-04-29 | Cytomx Therapeutics, Inc. | Aktivacijska protitelesa anti-CD71 in njihovi načini uporabe |
SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
EA034582B1 (ru) * | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药(上海)有限公司 | 可活化的嵌合受体 |
EP3368559A4 (en) | 2015-10-30 | 2020-01-15 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER |
CA3003144A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
EP3903818A1 (en) | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
CN109068621B (zh) | 2016-02-29 | 2021-07-20 | 再生元制药公司 | 具有人源化的tmprss基因的啮齿类动物 |
BR112019008223A2 (pt) | 2016-11-03 | 2019-07-16 | Bristol-Myers Squibb Company | anticorpos anti-ctla-4 ativáveis e usos dos mesmos |
WO2018097308A1 (ja) | 2016-11-28 | 2018-05-31 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
TWI797097B (zh) | 2016-11-28 | 2023-04-01 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
SG10201912560YA (en) | 2016-12-07 | 2020-02-27 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
BR112019011564A2 (pt) | 2016-12-09 | 2019-10-22 | Seattle Genetics Inc | anticorpos bivalentes mascarados por hélices superenroladas |
JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
EP3668545A2 (en) | 2017-08-16 | 2020-06-24 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
WO2019051102A2 (en) | 2017-09-08 | 2019-03-14 | Maverick Therapeutics, Inc. | BOND PROTEINS WITH RESTRICTED CONDITIONAL ACTIVATION |
WO2019075187A1 (en) * | 2017-10-12 | 2019-04-18 | The Trustees Of Princeton University | METHODS OF TREATING OR PREVENTING BREAST CANCER METASTASES USING ANTIBODIES AGAINST JAGGED1 AND CHEMOTHERAPEUTIC AGENTS |
BR112020007309A2 (pt) | 2017-10-14 | 2020-09-29 | Cytomx Therapeutics, Inc. | anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos |
TW201936208A (zh) | 2017-11-28 | 2019-09-16 | 日商中外製藥股份有限公司 | 含有抗原結合域及運輸部分之多胜肽 |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
CR20200391A (es) | 2018-02-08 | 2020-10-19 | Genentech Inc | Moléculas biespecíficas de unión al antígeno y métodos de uso |
US20200405890A1 (en) * | 2018-02-21 | 2020-12-31 | Cytomx Therapeutics, Inc. | Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof |
CN112005304A (zh) | 2018-03-20 | 2020-11-27 | 西托姆克斯治疗公司 | 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法 |
ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
CA3100018A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
US20210236636A1 (en) | 2018-07-31 | 2021-08-05 | Amgen Inc. | Pharmaceutical formulations of masked antibodies |
JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス,インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
EP3934762A1 (en) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
US20220288223A1 (en) * | 2019-03-12 | 2022-09-15 | The Regents Of The University Of California | Activatable specific binding member complexes, and methods of making and using same |
AU2020275877A1 (en) | 2019-05-14 | 2021-12-23 | Werewolf Therapeutics, Inc. | Separation moieties and methods and use thereof |
WO2020243338A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
AU2020384375A1 (en) | 2019-11-14 | 2022-05-26 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
IL293423A (en) | 2019-12-13 | 2022-07-01 | Genentech Inc | Anti-ly6g6d antibodies and methods of use |
CN115427113A (zh) | 2020-04-09 | 2022-12-02 | 西托姆克斯治疗公司 | 含有可活化抗体的组合物 |
AU2022367525A1 (en) | 2021-10-15 | 2024-05-02 | Amgen Inc. | Activatable polypeptide complex |
US11958906B2 (en) | 2022-04-13 | 2024-04-16 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US5869282A (en) | 1991-12-11 | 1999-02-09 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of the serrate gene and methods based thereon |
US6004924A (en) | 1991-12-11 | 1999-12-21 | Imperial Cancer Research Technology, Ltd. | Protein sequences of serrate gene products |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6025130A (en) | 1996-04-04 | 2000-02-15 | Mercator Genetics, Inc. | Hereditary hemochromatosis gene |
EP0921818A4 (en) | 1996-05-31 | 2002-09-25 | Nat American Red Cross | THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON JAGGED / NOTCH PROTEINS AND AMINO ACIDS |
AU720930B2 (en) | 1996-07-16 | 2000-06-15 | Asahi Kasei Kabushiki Kaisha | Differentiation inhibitor |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6562958B1 (en) | 1998-06-09 | 2003-05-13 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics |
US7504490B1 (en) | 1998-10-16 | 2009-03-17 | Oscient Pharmaceuticals Corporation | Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
EP1324771B2 (en) | 2000-10-09 | 2018-06-06 | CytomX Therapeutics, Inc. | Therapeutic and tolerance inducing antibodies |
US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
WO2003006614A2 (en) | 2001-07-12 | 2003-01-23 | Exelixis, Inc. | UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
AU2003265866A1 (en) | 2002-09-03 | 2004-03-29 | Vit Lauermann | Targeted release |
EP2233926A3 (en) | 2003-04-01 | 2011-01-12 | The Johns Hopkins University | Breast Endothelial Cell Expression Patterns |
JP2006525026A (ja) | 2003-05-02 | 2006-11-09 | ヘルス リサーチ インコーポレイテッド | 形質細胞疾患の診断におけるjag2の発現の使用 |
WO2005054434A2 (en) | 2003-11-26 | 2005-06-16 | Health Research, Inc. | Use of notch pathway interfering agents for treatment of plasma cell disorders |
WO2007085815A2 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
CA2645347A1 (en) | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
US8802103B2 (en) | 2007-05-15 | 2014-08-12 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
WO2009091518A2 (en) | 2008-01-15 | 2009-07-23 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgenic plant with enhanced agronomic traits |
US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
EP2385955B1 (en) | 2009-01-12 | 2020-08-12 | CytomX Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
EP2427479B1 (en) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Antibodies and methods of use thereof |
US8945569B2 (en) * | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
CA2868747A1 (en) | 2012-03-29 | 2013-10-03 | Robert J. Fleming | Methods and compositions for modulating notch activity |
RU2018130986A (ru) | 2012-08-13 | 2018-10-09 | Дженентек, Инк. | Антитела к jagged и способы их применения |
RU2015132436A (ru) * | 2013-01-04 | 2017-02-09 | Сайтомкс Терапьютикс, Инк. | Способы обнаружения активности протеазы в биологических системах и композиции для их осуществления |
-
2013
- 2013-06-21 CA CA2876904A patent/CA2876904C/en not_active Expired - Fee Related
- 2013-06-21 KR KR1020157001567A patent/KR20150037857A/ko not_active Application Discontinuation
- 2013-06-21 JP JP2015518613A patent/JP2015521625A/ja active Pending
- 2013-06-21 IN IN2635MUN2014 patent/IN2014MN02635A/en unknown
- 2013-06-21 US US13/923,935 patent/US9127053B2/en not_active Expired - Fee Related
- 2013-06-21 PE PE2014002517A patent/PE20150643A1/es not_active Application Discontinuation
- 2013-06-21 RU RU2015101803A patent/RU2015101803A/ru not_active Application Discontinuation
- 2013-06-21 WO PCT/US2013/047109 patent/WO2013192550A2/en active Application Filing
- 2013-06-21 EP EP13807400.0A patent/EP2863948B1/en active Active
- 2013-06-21 AU AU2013278075A patent/AU2013278075B2/en not_active Ceased
- 2013-06-21 CN CN201380043521.9A patent/CN104661677A/zh active Pending
- 2013-06-21 SG SG11201408554QA patent/SG11201408554QA/en unknown
- 2013-06-21 BR BR112014031689A patent/BR112014031689A2/pt not_active IP Right Cessation
- 2013-06-21 MX MX2014016038A patent/MX2014016038A/es unknown
-
2014
- 2014-12-18 IL IL236348A patent/IL236348A0/en unknown
- 2014-12-22 CO CO14280541A patent/CO7151488A2/es unknown
-
2015
- 2015-01-21 PH PH12015500125A patent/PH12015500125A1/en unknown
- 2015-06-01 HK HK15105219.7A patent/HK1204576A1/xx not_active IP Right Cessation
- 2015-07-31 US US14/815,167 patent/US9688748B2/en not_active Expired - Fee Related
-
2017
- 2017-06-23 US US15/631,116 patent/US10301380B2/en not_active Expired - Fee Related
-
2019
- 2019-04-05 US US16/376,252 patent/US20190367589A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170298125A1 (en) | 2017-10-19 |
US10301380B2 (en) | 2019-05-28 |
MX2014016038A (es) | 2015-08-14 |
US9127053B2 (en) | 2015-09-08 |
EP2863948A4 (en) | 2016-03-09 |
US20160200826A1 (en) | 2016-07-14 |
US20140010810A1 (en) | 2014-01-09 |
BR112014031689A2 (pt) | 2017-07-25 |
IL236348A0 (en) | 2015-02-26 |
KR20150037857A (ko) | 2015-04-08 |
US20190367589A1 (en) | 2019-12-05 |
CN104661677A (zh) | 2015-05-27 |
RU2015101803A (ru) | 2016-08-20 |
CA2876904A1 (en) | 2013-12-27 |
IN2014MN02635A (es) | 2015-10-16 |
US9688748B2 (en) | 2017-06-27 |
AU2013278075B2 (en) | 2018-05-17 |
PE20150643A1 (es) | 2015-05-29 |
AU2013278075A1 (en) | 2015-01-22 |
CA2876904C (en) | 2019-12-03 |
JP2015521625A (ja) | 2015-07-30 |
EP2863948A2 (en) | 2015-04-29 |
CO7151488A2 (es) | 2014-12-29 |
HK1204576A1 (en) | 2015-11-27 |
WO2013192550A3 (en) | 2014-04-24 |
EP2863948B1 (en) | 2018-10-24 |
WO2013192550A2 (en) | 2013-12-27 |
PH12015500125A1 (en) | 2015-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408554QA (en) | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof | |
IL256716A (en) | Antibodies against hla–b*27 and their uses | |
HK1209373A1 (en) | Anti-ly6e antibodies and immunoconjugates and methods of use ly6e | |
HK1205195A1 (en) | Cd47 antibodies and methods of use thereof cd47 | |
ZA201407927B (en) | Anti-egfr antibodies and uses thereof | |
HRP20190358T1 (hr) | Antitijela protiv asic1 i njihova primjena | |
IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
IL233757A0 (en) | Anti '1m e-gi antibodies and methods of using them | |
EP2830660A4 (en) | ANTI-SEMA4D ANTIBODIES AND EPITOPES | |
EP2874650A4 (en) | FOR CD22 SPECIFIC ANTIBODIES AND METHOD FOR USE THEREOF | |
PL2831117T3 (pl) | Przeciwciała anty-TLR4 i ich zastosowania | |
EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
GB201208372D0 (en) | Antibodies and uses thereof |